NCT06830213

Brief Summary

FMF is associated with many different clinical entities. The disease appears to be associated with many diseases and/or syndromes with common features of genetic predisposition, immune dysfunction and autoinflammation. Pericardial inflammation, cardiovascular conditions such as ischaemic heart disease, other rheumatic diseases such as ankylosing spondylitis (AS), vasculitis, especially Behçet's disease, malignancy and infertility are often associated with FMF. Early detection of these associations makes it possible to improve the management and prognosis of patients with FMF. The chronic nature of the disease, as in other chronic diseases, includes problems such as pain, fatigue, sleep problems, loss of function, anxiety, depression and social isolation. This complex structure is accompanied by a picture in which inflammatory processes are triggered. When the literature is examined, it is emphasised that chronic diseases with multifaceted symptoms require evaluation and methods that include all these biopsychosocial features. On the other hand, although it is stated that the common goal of non-pharmacological treatments is to contribute to biopsychosocial improvement in the patient, it is emphasised that evaluations with biopsychosocial content are insufficient. This situation causes the need for scales that provide an assessment from a holistic perspective in chronic diseases. Cognitive Exercise Therapy Approach (BETY) is an innovative exercise approach developed on the basis of biopsychosocial model on individuals with rheumatism. The parameters that constitute the innovation are detailed under four headings: function-oriented core stabilisation exercises, information management in pain, information management in mood, and information management in sexuality. This method has a unique scale that offers biopsychosocial assessment. The Cognitive Exercise Therapy Approach - Biopsychosocial Questionnaire (BETY-BQ) was created by receiving feedback from individuals with rheumatism who participated in BETY exercise training 3 days a week for many years, expressing the improvement characteristics they experienced by participating in exercise sessions. The BETY-BQ evaluates the individual biopsychosocially with six sub-headings: pain, functionality-fatigue, emotion-state, sociability, sexuality and sleep. The validity, reliability and sensitivity of the BETY-BQ have been demonstrated in many rheumatic diseases such as rheumatoid arthritis, fibromyalgia, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, knee osteoarthritis, primary Sjögren's syndrome. Currently, it is clear that there is a need for scales that offer biopsychosocial assessment for individuals diagnosed with rheumatism, where biopsychosocial approaches are recommended in EULAR recommendations. BETY-BQ is included in the EULAR library as a biopsychosocial status measurement tool. This study will investigate the validity, reliability and responsiveness of the BETY-BQ, a biopsychosocial assessment tool, in individuals diagnosed with Familial Mediterranean Fever.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
20mo left

Started Feb 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress42%
Feb 2025Dec 2027

First Submitted

Initial submission to the registry

February 11, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 17, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

February 18, 2025

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2027

Expected
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

February 19, 2025

Status Verified

December 1, 2024

Enrollment Period

2.1 years

First QC Date

February 11, 2025

Last Update Submit

February 16, 2025

Conditions

Keywords

Familial Mediterranean Feverbiopsychosocialdepressionsocial isolationpainsleepfunctionality

Outcome Measures

Primary Outcomes (1)

  • BETY-Biopsychosocial Questionnaire

    The biopsychosocial status of the individual is assessed with questions about pain, functionality, mood, sociability, sexuality, and sleep status. Each question consists of 30 items scored between 0-120 as '0 (never), 1 (yes rarely), 2 (yes sometimes), 3 (yes often), 4 (yes always)'. A high score indicates poor biopsychosocial status

    3 mounths

Secondary Outcomes (5)

  • Hospital Anxiety Depression Scale

    3 mounths

  • Health Assessment Questionnaire

    3 mounths

  • Short Form - 36

    3 mounths

  • Pain Catastrophizing Scale

    3 mounths

  • Fatigue Severity Scale

    3 mounths

Interventions

Questionnaire application

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population will consist of individuals who come to the university hospital for routine controls.

You may qualify if:

  • Having a diagnosis of Familial Mediterranean Fever
  • Being literate
  • Being 18 years of age or older
  • Having read and signed the informed consent

You may not qualify if:

  • History of major psychiatric illness
  • Malignant disease
  • History of peripheral vascular disease or neuropathy
  • Not volunteering for the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hacettepe University

Ankara, Altındağ, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Familial Mediterranean FeverDepressionSocial IsolationPain

Condition Hierarchy (Ancestors)

Hereditary Autoinflammatory DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesBehavioral SymptomsBehaviorSocial BehaviorNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Aysima Barlak, Licence

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
PT

Study Record Dates

First Submitted

February 11, 2025

First Posted

February 17, 2025

Study Start

February 18, 2025

Primary Completion (Estimated)

March 30, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

February 19, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations